• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Alpha Tau Medical Ltd.

    3/12/25 4:02:20 PM ET
    $DRTS
    Medical/Dental Instruments
    Health Care
    Get the next $DRTS alert in real time by email
    6-K 1 ea0233552-6k_alpha.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 6-K

     

     

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO SECTION 13A-16 OR 15D-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of March 2025

     

    Commission File Number: 001-41316

     

     

     

    Alpha Tau Medical Ltd.

    (Exact Name of Registrant as Specified in Its Charter)

     

     

     

    Kiryat HaMada St. 5

    Jerusalem, Israel 9777605

    +972 (3) 577-4115

    (Address of principal executive offices)

     

     

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ☒     Form 40-F ☐

     

     

     

     

     

    CONTENTS

     

    On March 12, 2025, Alpha Tau Medical Ltd. (the “Company”) issued a press release titled “Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update.” A copy of this press release is attached to this Form 6-K as Exhibit 99.1.

     

    The financial information included in the consolidated balance sheets and consolidated statements of operations contained in the press release attached as Exhibit 99.1 to this report on Form 6-K is hereby incorporated by reference into the registrant’s Registration Statements on Form F-3 (File Nos. 333-271073, 333-264306 and 333-274457) and Form S-8 (File Nos. 333-264169, 333-270406 and 333-277733).

     

    1

     

    EXHIBIT INDEX

     

    Exhibit No.   Description
    99.1   Press release dated March 12, 2025.

     

    2

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      Alpha Tau Medical Ltd.
         
    Date: March 12, 2025 By: /s/ Uzi Sofer
        Uzi Sofer
        Chief Executive Officer

     

    3

     

    Get the next $DRTS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DRTS

    DatePrice TargetRatingAnalyst
    12/15/2023$8.00Buy
    Citigroup
    4/24/2023$9.00Buy
    H.C. Wainwright
    4/14/2022$20.00Overweight
    Cantor Fitzgerald
    4/8/2022$19.00Overweight
    Piper Sandler
    4/4/2022$21.00Buy
    Citigroup
    More analyst ratings

    $DRTS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alpha Tau to Participate in May Investor Conferences

      JERUSALEM, May 06, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW)), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will presentation in the following investor conferences in May 2025. Event:H.C. Wainwright 3rd Annual BioConnect Investor ConferenceFormat:Fireside ChatDate:May 20, 2025Time:3:30 – 4:00PM ETLocation:New York, NY Event:Lytham Partners Spring 2025 Investor ConferenceFormat:1x1 MeetingsDate:May 29, 2025Location:Virtual Mr. Levy will be available for 1x1 investor meetings at both conferences. Please reach out to your H.C. Wainwright and Lytham Partners representa

      5/6/25 8:30:00 AM ET
      $DRTS
      Medical/Dental Instruments
      Health Care
    • Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical

      Oramed leverages its strategic capital markets expertise to support Alpha Tau's breakthrough cancer therapy technology Accelerating multiple late-stage cancer therapies including: US clinical trials across four indications, manufacturing scale-up, and commercialization efforts Partnership unites two innovative therapeutic delivery pioneers – Oramed's oral drug delivery platform with Alpha Tau's precision radiation delivery technology NEW YORK, April 28, 2025 /PRNewswire/ -- Oramed Pharmaceuticals Inc. ("Oramed" or the "Company"), (NASDAQ:ORMP) (TASE: ORMP), a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection, announced today that

      4/28/25 9:00:00 AM ET
      $DRTS
      $ORMP
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals

      JERUSALEM, April 28, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW)), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that it has successfully closed a registered direct offering (the "offering") whereby an affiliate of Oramed Pharmaceuticals Inc. ("Oramed") (NASDAQ:ORMP) (TASE: ORMP) purchased 14,110,121 of Alpha Tau's ordinary shares, no par value, at a purchase price of $2.612 per ordinary share. The offering closed on April 28, 2025.   The total gross proceeds of the offering were approximately $36.9 million, before deducting estimated offering expenses payable by Alpha Tau. Alpha Tau int

      4/28/25 9:00:00 AM ET
      $DRTS
      $ORMP
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $DRTS
    SEC Filings

    See more
    • SEC Form 6-K filed by Alpha Tau Medical Ltd.

      6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)

      5/6/25 8:32:02 AM ET
      $DRTS
      Medical/Dental Instruments
      Health Care
    • SEC Form SCHEDULE 13D filed by Alpha Tau Medical Ltd.

      SCHEDULE 13D - Alpha Tau Medical Ltd. (0001871321) (Subject)

      5/1/25 1:59:57 PM ET
      $DRTS
      Medical/Dental Instruments
      Health Care
    • SEC Form 6-K filed by Alpha Tau Medical Ltd.

      6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)

      4/28/25 9:20:18 AM ET
      $DRTS
      Medical/Dental Instruments
      Health Care

    $DRTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citigroup initiated coverage on Alpha Tau with a new price target

      Citigroup initiated coverage of Alpha Tau with a rating of Buy and set a new price target of $8.00

      12/15/23 8:07:49 AM ET
      $DRTS
      Medical/Dental Instruments
      Health Care
    • H.C. Wainwright initiated coverage on Alpha Tau with a new price target

      H.C. Wainwright initiated coverage of Alpha Tau with a rating of Buy and set a new price target of $9.00

      4/24/23 7:44:43 AM ET
      $DRTS
      Medical/Dental Instruments
      Health Care
    • Cantor Fitzgerald initiated coverage on Alpha Tau with a new price target

      Cantor Fitzgerald initiated coverage of Alpha Tau with a rating of Overweight and set a new price target of $20.00

      4/14/22 7:17:36 AM ET
      $DRTS
      Medical/Dental Instruments
      Health Care

    $DRTS
    Leadership Updates

    Live Leadership Updates

    See more
    • Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update

      - Interim results from three trials exploring the use of Alpha DaRT® in treating pancreatic cancer showing high disease control rate, impressive overall survival in sub-group analyses, and positive safety profile - - Systemic ORR and complete response rates meaningfully higher thus far than historical Keytruda® monotherapy data in interim read out of a combination trial of Alpha DaRT and Keytruda in treating recurrent unresectable or metastatic head and neck squamous cell carcinoma (HNSCC) - - Interim data from pancreatic cancer trials presented at the prestigious 2025 ASCO GI Symposium - - FDA approval of Investigational Device Exemption (IDE) and IDE supplement t

      3/12/25 4:02:00 PM ET
      $DRTS
      Medical/Dental Instruments
      Health Care
    • Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor

      JERUSALEM, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ:DRTS, DRTSW)), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that following its Annual General Meeting of Company shareholders in Jerusalem, Ms. Maya Netser has been appointed to the Company's Board of Directors ("Board"). Mr. Meir Jakobsohn is completing his term on the Board, having decided not to pursue re-election, but will continue to serve the Company in an advisory capacity. "I am delighted to welcome Maya to the Board," said Company CEO and Chairman of the Board Mr. Uzi Sofer. "Maya brings a wealth of experience and a keen under

      12/17/24 9:00:00 AM ET
      $DRTS
      Medical/Dental Instruments
      Health Care
    • Alpha Tau Appoints Industry Veteran Peter Melnyk as Chief Commercial Officer

      JERUSALEM, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ:DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that Peter Melnyk, a member of its board of directors, has resigned from the Company's Board of Directors in order to assume the full-time position of Alpha Tau's Chief Commercial Officer. Mr. Melnyk served most recently as CEO of Fortovia Therapeutics, an oncology supportive care pharmaceutical and medical device company headquartered in Raleigh, North Carolina. Before that, he served as Chief Commercial Officer of Novocure, and led the construction of the global commercial platform and infrastructure

      9/1/22 4:15:42 PM ET
      $DRTS
      Medical/Dental Instruments
      Health Care